<br>        Inclusion Criteria:<br><br>          -  Subjects who met study entry criteria and completed 8-week induction treatment from<br>             Study A3921094 or A3921095<br><br>          -  Subjects who achieved clinical response in Study A3921094 or A3921095<br><br>          -  Women of childbearing potential must test negative for pregnancy prior to study<br>             enrollment<br><br>          -  Subjects who are willing and able to comply with scheduled visits, treatment plan,<br>             laboratory tests, and other study procedures<br><br>          -  Evidence of a personally signed and dated informed consent document(s) indicating that<br>             the subject (or a legally acceptable representative) has been informed of all<br>             pertinent aspects of the study.<br><br>        Exclusion Criteria:<br><br>          -  Subjects who had major protocol violation (as determined by the Sponsor) in Study<br>             A3921094 or A3921095<br><br>          -  Presence of indeterminate colitis, microscopic colitis, ischemic colitis, infectious<br>             colitis, or clinical findings suggestive of Crohn's disease<br><br>          -  Subjects who have had surgery for UC or in the opinion of the investigator, are likely<br>             to require surgery for UC during the study period.<br>      ;<br>        Inclusion Criteria:<br><br>          -  Subjects who met study entry criteria and completed 8-week induction treatment from<br>             Study A3921094 or A3921095<br><br>          -  Subjects who achieved clinical response in Study A3921094 or A3921095<br><br>          -  Women of childbearing potential must test negative for pregnancy prior to study<br>             enrollment<br><br>          -  Subjects who are willing and able to comply with scheduled visits, treatment plan,<br>             laboratory tests, and other study procedures<br><br>          -  Evidence of a personally signed and dated informed consent document(s) indicating that<br>             the subject (or a legally acceptable representative) has been informed of all<br>             pertinent aspects of the study.<br><br>        Exclusion Criteria:<br><br>          -  Subjects who had major protocol violation (as determined by the Sponsor) in Study<br>             A3921094 or A3921095<br><br>          -  Presence of indeterminate colitis, microscopic colitis, ischemic colitis, infectious<br>             colitis, or clinical findings suggestive of Crohn's disease<br><br>          -  Subjects who have had surgery for UC or in the opinion of the investigator, are likely<br>             to require surgery for UC during the study period.<br>      ;<br>        Inclusion Criteria:<br><br>          -  Subjects who met study entry criteria and completed 8-week induction treatment from<br>             Study A3921094 or A3921095<br><br>          -  Subjects who achieved clinical response in Study A3921094 or A3921095<br><br>          -  Women of childbearing potential must test negative for pregnancy prior to study<br>             enrollment<br><br>          -  Subjects who are willing and able to comply with scheduled visits, treatment plan,<br>             laboratory tests, and other study procedures<br><br>          -  Evidence of a personally signed and dated informed consent document(s) indicating that<br>             the subject (or a legally acceptable representative) has been informed of all<br>             pertinent aspects of the study.<br><br>        Exclusion Criteria:<br><br>          -  Subjects who had major protocol violation (as determined by the Sponsor) in Study<br>             A3921094 or A3921095<br><br>          -  Presence of indeterminate colitis, microscopic colitis, ischemic colitis, infectious<br>             colitis, or clinical findings suggestive of Crohn's disease<br><br>          -  Subjects who have had surgery for UC or in the opinion of the investigator, are likely<br>             to require surgery for UC during the study period.<br>      ;<br>        Inclusion Criteria:<br><br>          -  Subjects who met study entry criteria and completed 8-week induction treatment from<br>             Study A3921094 or A3921095<br><br>          -  Subjects who achieved clinical response in Study A3921094 or A3921095<br><br>          -  Women of childbearing potential must test negative for pregnancy prior to study<br>             enrollment<br><br>          -  Subjects who are willing and able to comply with scheduled visits, treatment plan,<br>             laboratory tests, and other study procedures<br><br>          -  Evidence of a personally signed and dated informed consent document(s) indicating that<br>             the subject (or a legally acceptable representative) has been informed of all<br>             pertinent aspects of the study.<br><br>        Exclusion Criteria:<br><br>          -  Subjects who had major protocol violation (as determined by the Sponsor) in Study<br>             A3921094 or A3921095<br><br>          -  Presence of indeterminate colitis, microscopic colitis, ischemic colitis, infectious<br>             colitis, or clinical findings suggestive of Crohn's disease<br><br>          -  Subjects who have had surgery for UC or in the opinion of the investigator, are likely<br>             to require surgery for UC during the study period.<br>